Why the study?
To provide an overview of real-world data on the use of tofacitinib in patients with active rheumatoid arthritis in Spain.
What are the real-world treatment patterns, effectiveness, and safety of tofacitinib in patients with active rheumatoid arthritis in Spain?
What are the real-world treatment patterns, effectiveness, and safety of tofacitinib in patients with active rheumatoid arthritis in Spain?
Real-world data from Spain confirms the effectiveness and safety profile of tofacitinib in rheumatoid arthritis, with herpes zoster as the most common adverse event.
Answers are grounded in this paper and cite their sources.
Spanish real-world tofacitinib data in RA summarized; leaves open efficacy and safety questions for prospective trials.
The purpose of this narrative review is to provide an overview of the real-world data on the use of tofacitinib in patients with active rheumatoid arthritis (RA) in Spain. Sixteen retrospective studies carried out in Spain between 2019 and 2021 have been analyzed, considering patients' characteristics, and treatment patterns, effectiveness, and safety. In those studies, approximately 511 patients received tofacitinib during the study period. They were predominantly women (mean age: 48-61 years). The percentage of patients receiving tofacitinib as monotherapy ranged between 20.0% and 67.9%. Only five studies reported the combined use of corticosteroids (42.0-84.5% of patients), with a mean dose varying from 1.8 to 7.2 mg. A wide range of patients (36.0-85.7%) had failed a previous biological disease-modifying anti-rheumatic drug. The most frequent reason for treatment discontinuation was the lack of efficacy, and the most common adverse event described was herpes zoster infection. Real-world studies complement clinical trials by adding efficacy and safety data in real-world settings to the benefit/risk profile of the drug. The profile of RA patients receiving tofacitinib in Spain has similarities with other real-world studies conducted in other countries.
No takes yet. Share an insight, caveat, or question.
Ivorra et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: